Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Michael G. Natchus Clear advanced filters

  • Measles virus infection causes immunosuppression and it’s unclear whether this can be prevented by antivirals. Here, using a canine distemper virus ferret model, the authors show that measles-like immune amnesia and lethal exacerbated respiratory disease after consecutive respiratory virus infections can be mitigated by oral antiviral therapy initiated at the onset of primary clinical signs.

    • Robert M. Cox
    • Josef D. Wolf
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16

  • There is limited data on how SARS-CoV-2 antivirals compare regarding efficacy and blocking transmission. Here, treating dwarf hamsters and ferrets with either molnupiravir or paxlovid the authors find comparable efficacy against severe COVID-19-like disease and complete block of transmission by molnupiravir.

    • Robert M. Cox
    • Carolin M. Lieber
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-14

  • Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.

    • Carolin M. Lieber
    • Robert M. Cox
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-13

  • Human and bat coronaviruses replicate efficiently in immunodeficient mice implanted with human lung tissue, and treatment or prophylaxis using EIDD-2801 in this model suggests that this oral antiviral agent may be effective in preventing COVID-19.

    • Angela Wahl
    • Lisa E. Gralinski
    • J. Victor Garcia
    Research
    Nature
    Volume: 591, P: 451-457